Researchers examined early itch and sleep outcomes with interleukin-31 pathway inhibition in atopic dermatitis and prurigo nodularis in phase 3 trial analyses.
A recent study in the Journal of Investigative Dermatology identified potential early factors in the development of hidradenitis suppurativa, involving apocrine gland damage and keratin release, offering insights into potential biomarkers for disease severity and progression.